Cargando…

Forodesine and Riboprine Exhibit Strong Anti-SARS-CoV-2 Repurposing Potential: In Silico and In Vitro Studies

[Image: see text] Lately, nucleos(t)ide antivirals topped the scene as top options for the treatment of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Targeting the two broadly conserved SARS-CoV-2 enzymes, RNA-dependent RNA...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rabie, Amgad M., Abdalla, Mohnad
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Chemical Society 2022
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9631343/ https://www.ncbi.nlm.nih.gov/pubmed/37582236 http://dx.doi.org/10.1021/acsbiomedchemau.2c00039

Ejemplares similares

Evaluation of a series of nucleoside analogs as effective anticoronaviral-2 drugs against the Omicron-B.1.1.529/BA.2 subvariant: A repurposing research study
por: Rabie, Amgad M., et al.
Publicado: (2022)

Promising Experimental Anti-SARS-CoV-2 Agent “SLL-0197800”: The Prospective Universal Inhibitory Properties against the Coming Versions of the Coronavirus
por: Rabie, Amgad M., et al.
Publicado: (2023)

Novel Investigational Anti-SARS-CoV-2 Agent Ensitrelvir “S-217622”: A Very Promising Potential Universal Broad-Spectrum Antiviral at the Therapeutic Frontline of Coronavirus Species
por: Eltayb, Wafa A., et al.
Publicado: (2023)

Dual computational and biological assessment of some promising nucleoside analogs against the COVID-19-Omicron variant
por: Abdalla, Mohnad, et al.
Publicado: (2023)

Strong Dual Antipolymerase/Antiexonuclease Actions of Some Aminothiadiazole Antioxidants: A Promising In-Silico/In-Vitro Repurposing Research Study against the COVID-19 Omicron Virus (B.1.1.529.3 Lineage)
por: Rabie, Amgad M., et al.
Publicado: (2023)

The Effects of Forodesine in Murine and Human Multiple Myeloma Cells
por: Bieghs, Liesbeth, et al.
Publicado: (2010)

Cyanorona-20: The first potent anti-SARS-CoV-2 agent
por: Rabie, Amgad M.
Publicado: (2021)

Repurposing benzimidazole and benzothiazole derivatives as potential inhibitors of SARS-CoV-2: DFT, QSAR, molecular docking, molecular dynamics simulation, and in-silico pharmacokinetic and toxicity studies
por: Mohapatra, Ranjan K., et al.
Publicado: (2021)

Forodesine in the treatment of relapsed/refractory peripheral T-cell lymphoma: an evidence-based review
por: Makita, Shinichi, et al.
Publicado: (2018)

Repurposing of Doxycycline to Hinder the Viral Replication of SARS-CoV-2: From in silico to in vitro Validation
por: Alexpandi, Rajaiah, et al.
Publicado: (2022)

In vitro and in silico evaluation of antiretrovirals against SARS-CoV-2: A drug repurposing approach
por: Zapata-Cardona, Maria I., et al.
Publicado: (2023)

Efficacious Preclinical Repurposing of the Nucleoside Analogue Didanosine against COVID-19 Polymerase and Exonuclease
por: Rabie, Amgad M.
Publicado: (2022)

Potent toxic effects of Taroxaz-104 on the replication of SARS-CoV-2 particles
por: Rabie, Amgad M.
Publicado: (2021)

Potent Inhibitory Activities of the Adenosine Analogue Cordycepin on SARS-CoV-2 Replication
por: Rabie, Amgad M.
Publicado: (2022)

Multicenter phase 1/2 study of forodesine in patients with relapsed peripheral T cell lymphoma
por: Maruyama, Dai, et al.
Publicado: (2018)

Transplacental transmission of SARS-CoV-2 infection via NRP1
por: El-Arabey, Amr Ahmed, et al.
Publicado: (2021)

Discovery of Taroxaz-104: The first potent antidote of SARS-CoV-2 VOC-202012/01 strain
por: Rabie, Amgad M.
Publicado: (2021)

Are the new SARS-CoV-2 variants resistant against the vaccine?
por: Abdalla, Mohnad, et al.
Publicado: (2021)

SAMHD1 Limits the Efficacy of Forodesine in Leukemia by Protecting Cells against the Cytotoxicity of dGTP
por: Davenne, Tamara, et al.
Publicado: (2020)

In Silico Drug Repurposing for SARS-CoV-2 Main Proteinase and Spike Proteins
por: Maffucci, Irene, et al.
Publicado: (2020)

In-Silico targeting of SARS-CoV-2 NSP6 for drug and natural products repurposing
por: Abdelkader, Ahmed, et al.
Publicado: (2022)

Anti-HIV drug repurposing against SARS-CoV-2
por: Sang, Peng, et al.
Publicado: (2020)

Potent Dual Polymerase/Exonuclease Inhibitory Activities of Antioxidant Aminothiadiazoles Against the COVID-19 Omicron Virus: A Promising In Silico/In Vitro Repositioning Research Study
por: Rabie, Amgad M., et al.
Publicado: (2023)

In Silico Screening of Potential Spike Glycoprotein Inhibitors of SARS-CoV-2 with Drug Repurposing Strategy
por: Wei, Tian-zi, et al.
Publicado: (2020)

Repurposing FDA-approved drugs against multiple proteins of SARS-CoV-2: An in silico study
por: Akinlalu, Alfred Olaoluwa, et al.
Publicado: (2021)

Above the Invasive and Ornamental Attributes of the Traveler’s Palm: An In Vitro and In Silico Insight into the Anti-Oxidant, Anti-Enzymatic, Cytotoxic and Phytochemical Characterization of Ravenala madagascariensis
por: Suroowan, Shanoo, et al.
Publicado: (2023)

Trigonella foenum-graecum Methanolic Extract on Isolated Smooth Muscles and Acetylcholinesterase Enzyme: An In Vitro and Mechanistic In Silico Investigation
por: Ghayur, Muhammad Nabeel, et al.
Publicado: (2022)

In silico identification of strong binders of the SARS-CoV-2 receptor-binding domain
por: Behloul, Nouredine, et al.
Publicado: (2021)

Targeting SARS-CoV-2 RNA-dependent RNA polymerase: An in silico drug repurposing for COVID-19
por: Baby, Krishnaprasad, et al.
Publicado: (2020)

In silico molecular docking analysis for repurposing therapeutics against multiple proteins from SARS-CoV-2
por: Deshpande, Rujuta R., et al.
Publicado: (2020)

Drug Repurposing for Candidate SARS-CoV-2 Main Protease Inhibitors by a Novel In Silico Method
por: Sencanski, Milan, et al.
Publicado: (2020)

Identification of potential inhibitors of SARS-CoV-2 S protein–ACE2 interaction by in silico drug repurposing
por: Tristán-Flores, Fabiola E, et al.
Publicado: (2021)

Proteomics advances towards developing SARS-CoV-2 therapeutics using in silico drug repurposing approaches
por: Mukherjee, Amrita, et al.
Publicado: (2021)

Integrative In Silico Investigation Reveals the Host-Virus Interactions in Repurposed Drugs Against SARS-CoV-2
por: Yu, Wenhui, et al.
Publicado: (2022)

Synergistic anti-SARS-CoV-2 activity of repurposed anti-parasitic drug combinations
por: Jitobaom, Kunlakanya, et al.
Publicado: (2022)

Aminoglycosides as potential inhibitors of SARS-CoV-2 main protease: an in silico drug repurposing study on FDA-approved antiviral and anti-infection agents
por: Ahmed, Mohammad Z., et al.
Publicado: (2021)

Anti–SARS‐CoV‐2 Repurposing Drug Database: Clinical Pharmacology Considerations
por: Zhang, Xinyuan, et al.
Publicado: (2021)

Molecular dynamic study of SARS-CoV-2 with various S protein mutations and their effect on thermodynamic properties
por: Abdalla, Mohnad, et al.
Publicado: (2022)

Ligand and structure-based virtual screening applied to the SARS-CoV-2 main protease: an in silico repurposing study
por: Ferraz, Witor Ribeiro, et al.
Publicado: (2020)

Structure- and Ligand-Based in silico Studies towards the Repurposing of Marine Bioactive Compounds to Target SARS-CoV-2
por: Fayed, Marwa A.A., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_6ia6a62i4av91v4klhp7j8mse9